Earnings and other concerns held some stocks back Thursday.
News & Analysis: Amicus Therapeutics
The company announced a significant stock offering.
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.
FOLD earnings call for the period ending March 31, 2019.
These growth companies could make a killing if their big bets pay off.
FOLD earnings call for the period ending December 31, 2018.
Amicus' shares crumbled with the broader market's decline last month, but the biotech has staged a stunning rally during the first few weeks of trading in 2019.
The company is expanding its pipeline of gene therapies.
A new treatment of Fabry disease could be available in the United States as soon as 2018.
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.